Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ly-Mee Yu

Showing results (171-180 of 185) with videos related to

Pageof 19
Sort By:
JAMA|May 3, 2022
Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical TrialKatherine L Tucker, Sam Mort, Ly-Mee Yu, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
BMJ Open|June 19, 2021
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher riskGail Hayward, Christopher C Butler, Ly-Mee Yu, et al.
Lancet (London, England)|August 13, 2021
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy-Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
The Lancet. Psychiatry|July 2, 2025
Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UKMichael Browning, Philip J Cowen, Ushma Galal, et al.
Trials|January 30, 2024
Using healthcare systems data for outcomes in clinical trials: issues to consider at the design stageAlice-Maria Toader, Marion K Campbell, Jennifer K Quint, et al.
The Lancet. Psychiatry|September 11, 2017
The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysisDaniel Freeman, Bryony Sheaves, Guy M Goodwin, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Jac-Antimicrobial Resistance|March 28, 2025
The impact of the COVID-19 pandemic on antimicrobial usage: an international patient-level cohort studyRefath Farzana, Stephan Jürgen Harbarth, Ly-Mee Yu, et al.
Pageof 19

Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
JAMA|May 3, 2022
Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical TrialKatherine L Tucker, Sam Mort, Ly-Mee Yu, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
BMJ Open|June 19, 2021
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher riskGail Hayward, Christopher C Butler, Ly-Mee Yu, et al.
Lancet (London, England)|August 13, 2021
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy-Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
The Lancet. Psychiatry|July 2, 2025
Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UKMichael Browning, Philip J Cowen, Ushma Galal, et al.
Trials|January 30, 2024
Using healthcare systems data for outcomes in clinical trials: issues to consider at the design stageAlice-Maria Toader, Marion K Campbell, Jennifer K Quint, et al.
The Lancet. Psychiatry|September 11, 2017
The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysisDaniel Freeman, Bryony Sheaves, Guy M Goodwin, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Jac-Antimicrobial Resistance|March 28, 2025
The impact of the COVID-19 pandemic on antimicrobial usage: an international patient-level cohort studyRefath Farzana, Stephan Jürgen Harbarth, Ly-Mee Yu, et al.
Pageof 19